𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus–infected liver transplant recipients

✍ Scribed by Salvador Benlloch; Laura Heredia; Claudia Barquero; José-Miguel Rayón; Ramón Pina; Victoria Aguilera; Martín Prieto; Marina Berenguer


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
182 KB
Volume
15
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


We previously developed a mathematical model, the Hospital Universitario La Fe (HULF) index, as an alternative to protocol liver biopsy (PLB) to estimate significant fibrosis (SF) in patients who underwent liver transplantation (LT) for liver damage caused by chronic HCV infection. In the present study, we sought to validate this noninvasive index. The commonly derived clinical and laboratory data for calculating the HULF index were prospectively collected over 2.7 years from patients undergoing LT and PLB. The sensitivity, specificity, positive and negative predictive values, and diagnostic capacity were evaluated with receiver operating characteristic curve analysis. Biopsy was performed 93 times in 86 LT patients. The prevalence of SF (F3-F4 on the Knodell scoring system) was 32%. The intraobserver and interobserver concordance was high ( ϭ 0.94 and ϭ 0.75, respectively) in identifying SF in PLB. For low scores, the HULF index discarded an SF diagnosis with a sensitivity of 90% and a negative predictive value of 89%. The area under the receiver operating characteristic curve was 0.68. The precision of the HULF index did not improve with the incorporation of donor age and body mass index into the multivariate analysis. Applying the index would have prevented 24% of the biopsy procedures performed. In conclusion, the HULF index was prospectively validated with data commonly obtained in standard clinical practice. Because the index distinguishes a subgroup of HCV LT patients with a low probability of having SF, PLB would be avoided in those patients.


📜 SIMILAR VOLUMES


Impact of tacrolimus versus cyclosporine
✍ Paul Martin; Ronald W. Busuttil; Robert M. Goldstein; Jeffrey S. Crippin; Goran 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

Hepatitis C virus (HCV)-induced cirrhosis is the commonest indication for orthotopic liver transplantation, but HCV recurrence is nearly universal and may worsen patient / graft outcomes. The frequency and severity of HCV recurrence has apparently increased in recent years, raising concern about a p

Rimantadine for treatment of hepatitis C
✍ Sherman, Kenneth E. ;Sickler, Joelle ;Aranda-Michel, Jaime ;Weber, Frederick L. 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 61 KB 👁 1 views

Hepatitis C recurrence after liver transplantation is a serious problem, leading to increased graft loss and morbidity in some individuals. Treatment with interferon and other agents is controversial and not highly efficacious. The use of an effective antiviral agent to reduce or eliminate viral bur

Hepatitis E virus infection as a cause o
✍ Sven Pischke; Pothakamuri V. Suneetha; Christine Baechlein; Hannelore Barg-Hock; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 1 views

Hepatitis E virus (HEV) infection induces self-limiting liver disease in immunocompetent individuals. Cases of chronic hepatitis E have recently been identified in organ transplant recipients. We questioned if chronic hepatitis E plays a role in graft hepatitis after liver transplantation in a low e

Fibrosis in liver as a predictive marker
✍ Akif Altınbaş; Şahin Coban; Osman Yüksel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 1 views

We read with great interest the article by Petta et al. 1 The compound 25-hydroxyvitamin D3 (25[OH]D3) was reported as an independent predictor of cardiovascular disease (by a decreased expression of profibrotic markers, and an increased expression of antifibrotic markers) despite the fact that its